A propensity- matched study was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.
A previous single arm phase II trial of our institution has shown that HFSRT combined with concurrent TMZ was safe and efficient for patients with BMs of ≥ 6cc in volume. The 1-year local control and overall survival rate was better than the results of a retrospective study using HFSRT alone in treating BMs of ≥ 3cm in diameter. Thus, we hypothesized that adding TMZ to HFSRT should translate to substantive benefits in clinical outcomes compared to HFSRT alone. Propensity score matching method was adopted to decrease potential bias in this retrospective study.
Study Type
OBSERVATIONAL
Enrollment
72
The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
Local tumor control rate (LTCR)
the control rate of treated lesions
Time frame: 3 months after radiation
Intracranial progression- free survival (IPFS)
the interval from the beginning of radiation to any intracranial progression
Time frame: up to 1 year
Local recurrence- free survival (LRFS)
the time from the beginning of radiation to local faliure.
Time frame: up to 1 year
Overall survival (OS)
the time from the beginning of radiation to follow-up or death
Time frame: up to 3 years
Progression- free survival (PFS)
the interval from the beginning of HFSRT to any progression of tumor.
Time frame: up to 1 year
Brain metastasis-specific survival (BMSS)
the internal from the beginning of radiation to death that caused by brain metastases.
Time frame: up to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.